Gel-electrofocusing in combination with immunodiffusion.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Carrel.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We have previously reported on the identification of a monoclonal antibody (mAb) directed against the human CD4 antigen which is capable of activating CD4+ peripheral blood T cells in the absence of other stimuli. In the present study, we extended these findings by demonstrating that the mAb, termed B66, was able to induce the production of interleukin-2 in murine T-cell hybridoma transfectants expressing the human CD4 glycoprotein. Moreover, we found that incubation of Jurkat cells with mAb B66 resulted in the nearly complete disappearance of both CD4 and CD3 from the cell surface, whereas modulation of CD4, but not CD3, was observed after incubation with a non-stimulatory anti-CD4 mAb. Similar results were obtained in modulation experiments using human CD4-expressing murine transfectants. It is thus conceivable that the stimulatory activity of anti-CD4 mAb B66 may be associated with an effect on the CD3 molecular complex. While the biochemical basis for the unique stimulatory activity of mAb B66 has yet to be defined, these findings provide direct evidence that cross-linking of CD4 alone may cause T-cell activation, thus supporting the notion that this glycoprotein can transduce independent positive signals upon binding to class II major histocompatibility complex molecules.
The human melanoma-associated antigen identified by the monoclonal antibody (mAb) Me14-D12 is a cell surface protein whose expression is induced by interferon-gamma (IFN-gamma). We have recently reported the molecular cloning of a genomic probe specific for the gene and mRNA of this protein. By screening with the genomic probe, we have now isolated a full length 3.0 kb cDNA from a Raji cell line-derived lambda-gt10 library. Sequence analysis of this cDNA showed a 99.8% homology with the intercellular adhesion molecule-1 (ICAM-1). Mouse Ltk- cells stably transfected with the human cDNA clone were found to express the ICAM-1 antigenic determinants detected by mAb Me14-D12 and a reference anti-ICAM-1 mAb, as judged by surface immunofluorescence. Immunoprecipitation of surface-iodinated proteins with mAb Me14-D12 revealed the presence of a 90 kD molecule with identical mobility to ICAM-1. In addition, mAb Me14-D12 could inhibit the phorbolester-stimulated aggregation of U937 cells. The findings show that the human melanoma-associated Me14-D12 antigen is the adhesion molecule ICAM-1.
The reactivity of four monoclonal antibodies (MAbs) directed against IFN-gamma inducible antigens with melanocytic cells was investigated in the course of local and systemic tumor progression of human malignant melanoma. Frozen sections of histologically defined melanocytic tissues at different stages of progression were stained with these MAbs using an indirect immunoperoxidase technique. The reactivity of MAbs Me15/B3 and Me15/F9, directed against two different epitopes of a 90-kDa molecule, was found to correlate with melanoma progression. Indeed, a significantly lower percentage of small than of advanced primary melanomas or metastases stained positively. A differential staining of nevocytic and dysplastic nevi was further observed for these two MAbs, which were also non-reactive with normal skin melanocytes. The reactivity of MAb Me14/D12, which identifies the intercellular adhesion molecule ICAM-1 and MAb Mel14/F12, directed against a 40-kDa molecule, was found to be independent of the Breslow thickness of primary melanomas. Both the latter MAbs stained a high proportion of nevocytic and dysplastic nevi. The co-expression of the surface molecules defined by MAbs Me14/D12, Me15/B3 and Me15/F9 in the course of melanoma progression was also analyzed. The frequency of this co-expression increased according to the Breslow thickness of primary melanomas. In addition, up to 100% of metastases, as opposed to 20% of dysplastic nevi, were found to be simultaneously stained by these three MAbs. It is therefore conceivable that high-risk melanocytic lesions might be identified by the use of a combination of MAbs directed against IFN-gamma regulated antigens.
The surface antigenic profile of 10 surgically removed uveal melanoma lesions and 5 conjunctival melanomas was analyzed with a panel of 22 monoclonal antibodies (mAbs) raised against membrane bound cutaneous melanoma-associated antigens (MAA). In addition these lesions were tested for their reactivity with mAbs against MHC class I and II molecules, CD7 (Pan-T) and CD10 (CALLA). The anti-MAA mAbs can be divided into two major groups: first those mAbs detecting markers expressed by the majority of uveal melanomas such as NKI-Beteb, NKI/C3, G7E2, M-2-2-4, Mel-14, G7A5, AMF6, AMF7, Pal M1, Pal M2, Me14/D12. The staining intensity for these mAbs was rather high, ranging in intensity between 70 and 100%. The second group of antibodies includes mAbs detecting markers not or very poorly expressed on ocular melanomas. The anti-ICAM-1 mAb P358 did not react with any of the lesions tested and mAb Muc18 and Muc54 only with one and two out of 15 lesions, respectively. The majority of spindle lesions and mixed type lesions and half of the epitheloid type lesions expressed HLA class I molecules, while HLA class II molecules were found on half of the spindle and epitheloid type lesions and on a small number of mixed cell type lesions. All spindle lesions were found to express the CD10 (CALLA) molecule and less than half of the other type of lesions were stained with an anti CD10 mAb. The melanoma associated ganglioside GD3 was mainly expressed on epitheloid type lesions while GD2 was predominantly expressed on mixed type lesions. In essence, the overall surface phenotype of the uveal melanoma lesions tested, as defined by the panel of mAbs used, differs markedly from the surface phenotype of cutaneous melanoma lesions defined by a very similar antibody panel.
During the development and testing of a radioreceptor assay (RRA) for human IL-1, we have detected and identified the presence of auto-antibodies to IL-1 in normal human plasma (NHP). The RRA is based on the competition between human 125I-labeled rIL-1 alpha and standard or unknown quantities of IL-1 alpha or IL-1 beta for binding to a limited amounts of IL-1 receptor (IL-1R) isolated from the EL4 mouse thymoma cell line. NHP from 20 out of 100 unselected blood donors were found to completely inhibit the binding of 125I-labeled IL-1 alpha to its receptor, suggesting the presence in these NHP samples of either abnormal amounts of IL-1 or of a factor binding to the 125I-labeled IL-1 alpha. Special care was taken to ascertain that the inhibitory factors were antibodies and not soluble IL-1 receptor antagonist. When plasma samples with inhibiting activity were incubated with labeled IL-1 alpha and chromatographed on a Sephadex G200 column, they were found to contain 125I-labeled complexes with an apparent molecular weight of 150-200kD. The IL-1 binding factor could be eliminated from plasma by incubation with protein A-Sepharose, suggesting that it consisted in IgG antibodies directed against IL-1. Furthermore, the antibody nature of the inhibiting factor was confirmed by its binding to purified rIL-1 coupled to Sepharose. Screening of 200 NHP samples by incubation with 100 pg of 125I-labeled IL-1 followed by precipitation with 12% of polyethylene glycol (PEG) confirmed that about 25% of NHP contain detectable IgG antibodies to IL-1 alpha, while only 2% of NHP contain antibodies to IL-1 beta. No correlation between the presence of these anti-IL-1 antibodies and any particular major histocompatibility complex or any pathological conditions was detected. We suggest that all serum samples assayed for IL-1 alpha or IL-1 beta content should be pretested with the PEG precipitation assay described here.
A panel of 8 new Mabs have been produced against neuroblastoma cells (LAN-1) previously treated with IFN-gamma. All selected Mabs from 2 different fusions have been shown to detect epitopes on the GD2 ganglioside molecules highly expressed on all cells of neural crest origin including neuroblastoma, glioblastoma and melanoma. Our results imply that modulation of GD2 exposure on NB cells is dependent on culture conditions and moreover that IFN-gamma increases the surface expression of GD2 and thereby enhances their immunogenicity.
Pleiotropic drug resistance is supposed to be associated with a particular tumor cell phenotype, defined by certain plasma membrane glycolipids. Therefore we wondered how far chemosensitivity in vitro correlates with phenotypic characteristics of melanoma cells, which are known to be highly refractory to cytocidal agents. 13 monolayer cell cultures of metastatic melanoma derived from 9 patients were tested with 12 monoclonal antibodies against constitutive, differentiation- and progression-associated antigens. In parallel these primary cell cultures were subjected to a proliferation inhibition assay in the presence of dacarbazine, cis-platinum and carboplatinum. Transferring melanoma cells from original tissue-suspensions into short-term monolayer cultures caused a change in the expression of certain tumor antigens in 54% of 104 assays. In addition, the incubation of the cultivated cells with various cytostatic agents caused them to alter their phenotype in 32% of 128 assays. Irrespective of the spontaneous or induced changes in the antigen patterns, cells lacking HLA-ABC and/or HLA-DR were inhibited more markedly by cytostatic agents as compared to those other cells expressing these antigens. The data suggest, that pretherapeutic determination of tumor cell phenotype may provide clinically useful information for therapeutic decisions in patients with metastatic melanoma.
Six monoclonal antibodies(Mabs) including 4 anti-melanoma, one anti-glioma, and one anti-HLA-DR have been tested in a 125I-protein A antibody binding assay using a panel of 34 different cell lines. This panel included 19 melanomas from different clinical and geographical origins, 10 fibroblast lines out of which 9 were established from melanoma patients, 2 glial cell lines, 1 osteosarcoma, 1 teratocarcinoma, and 1 murine melanoma. The reactivity pattern of the 4 anti-melanoma Mabs showed that they were not directed against antigens strictly restricted to melanoma, but rather against antigenic structures preferentially expressed on melanoma cells. These Mabs were found to crossreact with gliomas, thus they seem to recognize neuroectoderm associated differentiation antigens. The high crossreactivity of the anti-glioma Mab for melanoma was confirmed in this study. As expected from the literature, HLA-DR antigens were found to be expressed on more than 50% of the melanoma lines tested. The cellular distribution of the antigens recognized by two anti-melanoma Mabs on melanoma cells could be visualized by an autoradiographic procedure. From the labeling pattern it was concluded that only a proportion of the cells, varying from 13 to 38%, expressed the relevant antigen.
We produced three monoclonal antibodies, BF7, GE2 and CG12, against cultured human glioma cells. Their specificity was tested by an indirect antibody-binding radioimmunoassay on a panel of glial and non-glial tumor cell lines. BF7 and GE2 react preferentially with glioma cells and, except for one colon carcinoma line, they do not bind to the control non-neuroectodermal cells; they appear to be directed against common malignant glioma associated antigens. CG12, the third monoclonal antibody, binds to the great majority of tumor cell lines of neuroectodermal origin and does not bind to any other cell lines tested.
Melanoma cells can secrete several cytokines and express various cell surface molecules, such as the intercellular adhesion molecule ICAM-1, class II histocompatibility antigens, and the CALLA antigen, typically found in cells of the immune system. We have investigated the possible expression of interleukin-2 (IL-2) receptors in melanoma using monoclonal antibodies specific for the p55/alpha chain (TAC antigen) and the p75/beta subunit. Flow cytometric analysis of cultured melanoma cells showed the presence of low levels of the TAC antigen and of the beta chain on the surface of several cell lines. Similar results were obtained in vivo by immunohistochemistry on cryosections prepared from cutaneous and ocular melanoma explants. Positive staining was observed for the alpha chain of the IL-2 receptor in a high percentage of tumour cells. The beta chain could also be detected, although in a limited number of specimens. Analysis of RNA from melanoma cell lines by Northern blot showed the presence of typical 4 Kb transcripts for the p75 subunit, while low-abundance message for the p55 chain could be detected using combined reverse transcription/polymerase chain reaction analysis. Together, these results suggest that melanoma cells may express high affinity receptors for IL-2.